JF
FATE icon

Jump Financial’s Fate Therapeutics FATE Stock Holding History

Jump Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-215,600
Closed -$707K – 1788
2024
Q2 		$707K Buy
+215,600
New +$944K 0.01% 972
2023
Q3 		– Sell
-362,053
Closed -$1.72M – 1966
2023
Q2 		$1.72M Buy
362,053
+104,653
+41% +$578K 0.06% 449
2023
Q1 		$1.47M Buy
257,400
+163,911
+175% +$989K 0.06% 461
2022
Q4 		$943K Buy
93,489
+2,979
+3% +$55.9K 0.05% 507
2022
Q3 		$2.03M Sell
90,510
-1,610
-2% -$46.5K 0.08% 379
2022
Q2 		$2.28M Buy
92,120
+45,102
+96% +$1.24M 0.1% 275
2022
Q1 		$1.82M Buy
+47,018
New +$1.82M 0.08% 318
2021
Q4 		– Sell
-30,121
Closed -$1.78M – 1484
2021
Q3 		$1.78M Buy
+30,121
New +$2.36M 0.13% 174

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Jump Financial's FATE Position: Q3 2024 in Review

Jump Financial sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 215,600 shares — an estimated $707K sold.

Jump Financial first reported a position in FATE in Q3 2021 and held it in 8 quarters. The position peaked at $2.28M in Q2 2022. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

  • Jump Financial reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jump Financial sold 215,600 Fate Therapeutics shares in Q3 2024, an estimated $707K.
  • Jump Financial first reported a position in Fate Therapeutics in Q3 2021 and held it in 8 quarters.
  • Jump Financial's Fate Therapeutics position peaked at $2.28M in Q2 2022.
  • 164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on Jump Financial's 13F filing for Q3 2024, filed 14 Nov 2024.